Viamet to Present Data Demonstrating the Efficacy and Safety of VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis at ISIDOG Congress 2017

Viamet Pharmaceuticals, Inc. today announced that results from the Company’s REVIVE study, a Phase 2b clinical trial of VT-1161 for the treatment of patients with recurrent vulvovaginal candidiasis (RVVC), will be highlighted in an oral presentation at the upcoming International Society for Infectious Diseases in Obstetrics and Gynaecology (ISIDOG) Congress being held October 26 to 29 in Vienna, Austria. The presentation will be given by Stephen Brand, Ph.D., Vice President of Clinical Development for Viamet Pharmaceuticals. VT-1161 is the Company’s novel inhibitor of fungal CYP51 that is highly potent against fungal species associated with RVVC. Approximately 5 to 8 percent of women of childbearing age suffer from RVVC, or recurrent vaginal yeast infections. There are currently no approved therapies in the United States for RVVC, which can lead to intense discomfort and a substantial negative impact on psychological well-being.